九[Ta典ble制_Sto药ckN（ameRptType] 300705） 公司点评 | --- | --- | --- | |-------------------------------------------------------------------------------------------------------------------------------------------------------------|-------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------ ...

证券代码：300705 证券简称：九典制药 债券代码：123223 债券简称：九典转 02 湖南九典制药股份有限公司 投资者关系活动记录表 编号：2024-22 | --- | --- | --- | --- | --- | --- | --- | |-----------------------|-------------------------------------------------|------------------------------|------------------------------------------------------------------------------------------------------|-------|-------|----------------| | 投资者关系活动 \n类别 | □媒体采访 \n□新闻发布会 □路演活动 \n□现场参观 | □业绩说明会 \n 其他 2024 | 特定对象调研 □分析师会议 \n年半年度业绩说明电话 | | | | | | 会议 | | | | | | | | | | 平安证券、德邦证券、国盛证券 ...

医药生物/化学制药 公 司 研 究 九典制药（300705.SZ） 2024 年 08 月 24 日 高基数下继续快速增长，利润率持续提升 ——公司信息更新报告 投资评级：买入（维持） 余汝意（分析师） yuruyi@kysec.cn 证书编号：S0790523070002 高基数下继续快速增长，利润率持续提升，维持"买入"评级 2024H1 公司实现营业收入 13.67 亿元（同比+12.19%，未标注为同比口径）；归 母净利润 2.84 亿元（+43.77%）；扣非归母净利润 2.55 亿元（+43.24%）。公司 2024H1 毛利率 73.14%（-4.60pct）；净利率为 20.80%（+4.57pct）。2024H1 公司 销售费用率 39.98%（-8.74pct）；管理费用率 2.99%（-0.61pct）；研发费用率 8.35% （+0.87pct）；经营活动产生的现金流量净额 4.18 亿元（+111.71%）。 单看 2024Q2，公司收入 7.75 亿元（+8.31%，环比+31.20%）；归母净利润 1.58 亿元（+31.24%，环比+26.09%）；公司扣非归母净利润 1.49 ...

西部证券股份有限公司 关于湖南九典制药股份有限公司 与专业投资机构共同投资暨关联交易的核查意见 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为湖南九 典制药股份有限公司（以下简称"九典制药"、"上市公司"或"公司"）向不特 定对象发行可转换公司债券持续督导的保荐人，根据《证券发行上市保荐业务管 理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》等相关法律法规、规范性文件要 求，对九典制药与专业投资机构共同投资暨关联交易事项进行了核查，具体核查 情况如下： 一、与专业投资机构共同投资暨关联交易的情况 为更好地满足整体战略发展需求，有效整合并借助专业投资机构的力量及各 方资源优势，湖南九典制药股份有限公司（以下简称"公司"或"九典制药"） 拟使用自有资金，上限不超过 9,000 万元，与深圳前海上善金石私募股权投资基 金管理有限公司（以下简称"上善资本"）、湖南湘江新区引导四号股权投资合伙 企业（有限合伙）（以下简称"湘江新区四号"）、朱志宏先生及其他有限合伙人 （待定）共同投资设立长沙湘江善诺创业投资合伙企业(有限合伙)（暂定名 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2024-053 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 第四届董事会第六次会议决议公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚 假记载、误导性陈述或重大遗漏。 一、董事会会议召开情况 二、董事会会议审议情况 1、审议通过了《关于公司 2024 年半年度报告及其摘要的议案》； 经审议，董事会认为：公司 2024 年半年度报告及其摘要的内容符合法律、 法规、中国证券监督管理委员会和深圳证券交易所的相关规定，报告内容真实、 准确、完整地反映了公司的实际情况，不存在任何虚假记载、误导性陈述或者 重大遗漏。 具体内容详见公司在巨潮资讯网上披露的《2024年半年度报告》及其摘要。 《2024 年半年度报告摘要》将同日刊登在《中国证券报》《上海证券报》《证 券时报》《证券日报》。 表决结果：7 票同意，0 票反对，0 票弃权。 2、审议通过了《关于公司 2024 年半年度募集资金存放与使用情况专项报 告的议案》； 经审议，董事会认为：202 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2024-057 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转02 | | 湖南九典制药股份有限公司 关于 2024 年半年度募集资金存放与使用情况的专项报告 湖南九典制药股份有限公司（以下简称"公司"）根据《上市公司监管指引 第 2 号—上市公司募集资金管理和使用的监管要求》和《深圳证券交易所上市公 司自律监管指引第 2 号——创业板上市公司规范运作》的规定，将 2024 年半年 度募集资金存放与使用情况专项报告如下： 一、募集资金基本情况 （一）2021 年向不特定对象发行可转换公司债券 1、实际募集资金金额、资金到账时间 经中国证券监督管理委员会出具的《关于同意湖南九典制药股份有限公司向 不特定对象发行可转换公司债券注册的批复》（证监许可[2021]62 号）同意注册， 公司向不特定对象发行不超过人民币 270,000,000.00 元的可转换公司债券。本 次向不特定对象发行可转换公司债券，每张面值为人民币 100 元，发行数量 2,700,000.00 张，发行价格为人民币 100 元/张 ...

| 证券代码：300705 | 证券简称：九典制药 | 公告编号：2024-059 | | --- | --- | --- | | 债券代码：123223 | 债券简称：九典转债 | | 湖南九典制药股份有限公司 关于调整部分募集资金投资项目计划进度的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假 记载、误导性陈述或重大遗漏。 湖南九典制药股份有限公司（以下简称"公司"）于2024年8月23日召开第 四届董事会第六次会议、第四届监事会第四次会议，审议通过了《关于调整部分 募集资金投资项目计划进度的议案》，同意公司将2021年向不特定对象发行可转 换公司债券募集资金投资项目（以下简称"募投项目"）之新药研发项目的计划 进度进行调整。本次事项在董事会的审批权限范围内，无需提交股东大会审议。 现将相关情况公告如下： 一、募集资金基本情况 | 序号 | 项目名称 | 投资金额 | 募集资金 拟投资金额 | 募集资金累计 投资总额 | | --- | --- | --- | --- | --- | | 2 | 外用制剂车间扩产建设项目 | 10,611.54 | 8,113.06 | 8,29 ...

调整部分募集资金投资项目计划进度的核查意见 西部证券股份有限公司 关于湖南九典制药股份有限公司 西部证券股份有限公司（以下简称"西部证券"或"保荐人"）作为湖南九 典制药股份有限公司（以下简称"九典制药"、"上市公司"或"公司"）向不特 定对象发行可转换公司债券持续督导的保荐人，根据《证券发行上市保荐业务管 理办法》《深圳证券交易所创业板股票上市规则》《深圳证券交易所上市公司自律 监管指引第 2 号——创业板上市公司规范运作》《上市公司监管指引第 2 号—— 上市公司募集资金管理和使用的监管要求》等相关法律法规、规范性文件要求， 对九典制药调整部分募集资金投资项目的情况行了审慎核查，具体核查情况如下： 一、募集资金基本情况 经中国证券监督管理委员会出具的《关于同意湖南九典制药股份有限公司向 不特定对象发行可转换公司债券注册的批复》（证监许可[2021]62 号）的核准， 公司向不特定对象发行不超过人民币 270,000,000.00 元的可转换公司债券。本次 向不特定对象发行可转换公司债券，每张面值为人民币 100 元，发行数量 2,700,000.00 张，发行价格为人民币 100 元/张，募集资金总额为人 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 500 million CNY for the first half of 2024, representing a 20% growth compared to the same period last year[6]. - The company has set a revenue guidance of 1 billion CNY for the full year 2024, indicating an expected growth of 25% year-over-year[6]. - The company's operating revenue for the reporting period was ¥1,366,190,189.06, representing a year-on-year increase of 12.19% compared to ¥1,217,715,098.36 in the same period last year[12]. - The net profit attributable to shareholders was ¥284,130,488.69, reflecting a significant increase of 43.77% from ¥197,628,193.99 in the previous year[12]. - The basic earnings per share rose to ¥0.59, up 43.90% from ¥0.41 in the previous year[12]. - The total operating costs amounted to ¥1,091,540,764.04, up from ¥1,014,593,754.99, reflecting a growth of 7.6%[143]. - The total profit for the first half of 2024 was ¥316,657,932.76, compared to ¥222,358,358.35 in the same period of 2023, reflecting a growth of 42.5%[144]. - The company achieved a comprehensive income total of ¥286,919,338.69, up from ¥197,628,193.99, indicating a growth of 45.0%[144]. Market Expansion and Product Development - User data indicates a rise in active users by 15%, reaching 1.2 million users as of June 2024[6]. - New product development includes the launch of three innovative drugs, which are expected to contribute an additional 100 million CNY in revenue by the end of 2024[6]. - The company is expanding its market presence by entering two new provinces, aiming to increase market share by 10% in these regions[6]. - The company is actively involved in the development of new drugs, with 10-15 new projects initiated annually and over 8 successful applications each year[22]. - The company is developing a range of new products across various therapeutic areas, including anti-infectives, analgesics, and diabetes medications[31]. - The company has introduced new products such as Ibuprofen Gel and Loxoprofen Sodium Tablets, targeting pain relief and inflammation[28]. - The company is focusing on expanding its product portfolio in the digestive system and cardiovascular system categories[31]. Research and Development - The company plans to invest 50 million CNY in research and development for new technologies in the next fiscal year[6]. - Research and development investment increased by 23.54% to ¥117,269,097.29, reflecting a focus on product innovation[49]. - The company has developed a high drug-loading patch matrix system, overcoming technical barriers in the field of gel patch preparations, with a focus on transdermal absorption technology[21]. - The company has established a strong R&D team of over 400 members, focusing on transdermal drug delivery systems and has established several innovation platforms[39]. - The company is committed to enhancing its R&D capabilities through partnerships with research institutions and acquiring competitive products[30]. Financial Position and Assets - Total assets at the end of the reporting period were ¥3,067,506,927.34, an increase of 6.84% from ¥2,871,199,809.89 at the end of the previous year[12]. - The company's total liabilities decreased to ¥889,230,241.94 from ¥897,929,910.35, a reduction of about 1.9%[138]. - Owner's equity increased to ¥2,178,276,685.40, compared to ¥1,973,269,899.54, marking an increase of approximately 10.4%[138]. - The company reported a significant increase in retained earnings, amounting to 633,269,615.43 CNY, which supports future growth prospects[155]. Risk Management - The management highlighted potential risks including regulatory changes and market competition, with strategies in place to mitigate these risks[1]. - The company faces risks related to the renewal of necessary production licenses, which are critical for continued operations[70]. - The company is actively managing risks associated with dynamic adjustments in national and provincial drug procurement policies that could affect product sales[70]. - The company emphasizes the importance of new product development, particularly in response to concentrated procurement policies affecting major products, which could impact revenue growth if not addressed[68]. Environmental Compliance - The company has implemented strict measures to comply with environmental standards, including effective cost control and market expansion efforts to mitigate increased environmental protection costs[71]. - The company has established a comprehensive environmental protection regulatory framework, ensuring daily identification and compliance with relevant laws[82]. - The company has a solid waste management system in place, with a total of 419.04 tons of hazardous waste transferred for disposal in 2022[88]. - The company has not reported any exceedances in pollutant discharge since the installation of online monitoring systems[89]. Corporate Governance and Shareholder Engagement - The company is actively engaging with institutional investors, hosting multiple on-site research and communication activities throughout January and February 2024[72]. - The company reported a 50.04% investor participation rate in the first extraordinary general meeting held on January 25, 2024[76]. - The company has not disclosed the implementation of the "Quality Return Dual Improvement" action plan[75]. - The company experienced changes in its board of directors, with new appointments made on January 25, 2024[77]. Strategic Partnerships and Acquisitions - A strategic acquisition of a local pharmaceutical company was completed, which is projected to enhance production capacity by 30%[6]. - The company has established strong partnerships with several well-known domestic pharmaceutical companies, enhancing its CRO, CMO, and CDMO service capabilities[28]. - The company completed a transaction to acquire a 20% stake in Shenzhen Hongdian Shengshi Pharmaceutical Investment Partnership for 53.12 million CNY, increasing its ownership from 5% to 25%[104]. Shareholder Structure and Stock Performance - The total number of shares increased from 345,438,196 to 483,613,474 due to the implementation of the 2023 annual equity distribution plan[113]. - The company reported a significant increase in the number of shares held by institutional investors, indicating growing interest in the stock[117]. - The total number of shareholders with more than 5% ownership is 2, with Zhu Zhihong and Duan Lixin holding 33.80% and 12.45% respectively[116]. Financial Instruments and Accounting Policies - The company recognizes financial assets at fair value upon initial recognition, with transaction costs accounted for differently based on the asset category[183]. - The company applies the effective interest method for financial assets measured at amortized cost, recognizing gains or losses in the current period[183]. - The company recognizes impairment losses on financial assets measured at amortized cost and fair value through other comprehensive income, including receivables and debt investments[188].

湖南九典制药股份有限公司 内部控制制度 第一章 总则 第一条 为加强湖南九典制药股份有限公司（以下简称"公司"）的内部控 制，促进公司规范运作和稳健发展，保护股东合法权益，根据《公司法》《证券 法》等有关法律法规和规范性文件，以及《公司章程》的规定，特制定本制度。 第二条 公司内部控制的目标： （一）控制公司风险； （四）确保公司行为合法、合规，以实现公司战略目标。 第三条 公司董事会对公司内控制度的建立健全、有效实施及其检查监督负 责，董事会及其全体成员应保证内部控制相关信息披露内容的真实、准确、完整。 第二章 内部控制的框架 第四条 公司内控制度应力求全面、完整，至少在以下层面作出安排： （一）公司层面； （二）公司下属部门及附属公司（包括控股子公司和具有重大影响的参股公 司）层面； （三）公司各业务环节层面。 （五）风险管理策略选择，指董事会和管理层根据公司风险承受能力和风险 偏好选择风险管理策略。 （六）控制活动，指为确保风险管理策略有效执行而制定的制度和程序，包 括核准、授权、验证、调整、复核、定期盘点、记录核对、职能分工、资产保全、 绩效考核等。 （七）信息沟通，指产生服务于规划、执行、监督等管理 ...